Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia

Autor: Raphael Preiss, Johannes Thaler, Petra Jilma, Ingrid Pabinger, Eva Mikušková, Peter Quehenberger, Stephan Kudrnovsky-Moser, Florian Roitner, Joachim Rettl, Nazanin Samadi, Paul Knoebl, Cihan Ay
Rok vydání: 2021
Předmět:
Zdroj: Thrombosis Research. 207:126-130
ISSN: 0049-3848
DOI: 10.1016/j.thromres.2021.09.017
Popis: BACKGROUND: Cases of ChAdOx1 nCoV-19 (AstraZeneca) vaccinated patients with thrombocytopenia, elevated D-dimer, and elevated platelet factor 4 (PF4) antibody levels with- and without thrombosis have been reported. No recommendations regarding the duration of anticoagulation have been made, because data on the long-term course beyond the first weeks is lacking. OBJECTIVE: To report on the treatment, medical course, and longitudinal follow-up of laboratory parameters in patients with vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). PATIENTS: We followed VIPIT patients with- (n = 3) and without (n = 3) venous thromboembolism fulfilling the aforementioned laboratory criteria. RESULTS: Elevated D-dimer (median: 35.10 µg/ml, range: 17.80-52.70), thrombocytopenia (42 G/l, 20-101), and strong positivity in the platelet factor 4 (PF4)/heparin-enzyme-immunoassay (2.42 optical density [OD], 2.06-3.13; reference range
Databáze: OpenAIRE